MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ypsomed Advances Drug-Delivery Devices to the Next Level

Image courtesy of Ypsomed YM_ON_YpsoMate-ON_003_main.jpg
The YpsoMate from Ypsomed
YpsoMate On’s integrated electronics are detachable from the syringe to support recycling, re-use, or take-back.

Ypsomed has found a way to balance patient convenience and connectivity with sustainability. The company has launched YpsoMate On, calling it “the world’s first autoinjector for prefilled syringes with integrated connectivity.” The new device also supports the company’s goal to have CO2-neutral production by 2030 and reach net-zero emissions along the entire value creation chain by 2040, Ypsomed reported in a news release.

All of YpsoMate On’s electronic components are situated in a “separable element” of the autoinjector, according to the company.

“YpsoMate On is designed with a focus on separability for take-back, re-use, or recycling of its components,” Didier Plaschy, PR & Marketing Communication Manager for Ypsomed, told MD+DI. “The connectivity module is integrated into the end cap and can be separated from the syringe and the device parts.

“Connectivity implies the use of materials, that aren’t per se sustainable. But we are convinced of the positive effects of digital health,” continued Plaschy. “So we’re trying to reduce to a max. And we have eco design principles in place seeking to reduce the product’s footprint.”

These principles include:

  • Sustainable materials and optimized supply chain that minimize the environmental footprint
  • Connectivity module and device components that can be recovered through take-back programs
  • Easy separation of battery and electronics to simplify recycling

YpsoMate On builds on Ypsomed’s previous connected autoinjector, the SmartPilot, as well as Ypsomate Zero, which Ypsomed called “the world’s first zero-carbon-emission prefilled autoinjector.”

“The SmartPilot is an add-on for existing pens, whereas the YpsoMate On is new in the way it that all the connectivity parts fully integrated,” said Plaschy.

Integrated connectivity is important for today’s market. “YpsoMate On includes an advanced Bluetooth proximity measurement protocol, which automatically connects the injection device and the smartphone. This simplifies the user journey by removing the need for pairing. The injection data is automatically transferred to the user's therapy management app and the associated cloud.”

Demand for digital health and connected devices continues to grow. Verified Market Research valued the global digital health market to be US$96,794.51 million in 2020 and predicts it will hit US$325,730.94 million by 2028, growing at a CAGR of 16.13% from 2021 to 2028.

TAGS: Packaging
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Find Filling Suppliers

Find contract manufacturers that provide filling for drug-delivery devices on the Qmed Directory, the world's only directory of pre-qualified medical device industry suppliers.